A Phase 1/2 Open-label Multicenter Study of the Combination of NKTR-214 and Nivolumab or the Combination of NKTR-214 Nivolumab and Ipilimumab in Patients With Select Locally Advanced or Metastatic Solid Tumor Malignancies



Study Overview

The purpose of this study is to test the safety, tolerability, and effectiveness (how well these drugs work together) of the study drug (NKTR-214) given together with Opdivo?.


Study Description

The purpose of this study is to study the safety, tolerability, and effectiveness of the study drug (NKTR-214) given together with Opdivo.

Additional Information:

Participants will be compensated for their participation.



Research Study Identifier: TX7957
ClinicalTrials.gov Identifier: NCT1705311414 (NKTR16-214-02)
Principal Investigator: Roberto Pili, MD


Currently Recruiting

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.